[8-K] Idexx Laboratories Inc Reports Material Event
Stoke Therapeutics, Inc. (Nasdaq: STOK) filed a Form 8-K on July 10, 2025 under Item 7.01 (Regulation FD). The filing states that the company issued a press release (Exhibit 99.1) announcing the presentation of data from an analysis that informed the design of the planned Phase 3 EMPEROR study and evaluated the potential effects of the proposed zorevunersen dosing regimen. No financial metrics, study results, or timelines were included in the 8-K. The information is furnished (not filed) and therefore is not incorporated by reference into other Exchange Act or Securities Act filings unless specifically stated.
Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la società ha diffuso un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione dei dati di un’analisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR pianificato e ha valutato i potenziali effetti del regime di dosaggio proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite (non depositate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell’Exchange Act o del Securities Act, salvo diversa indicazione.
Stoke Therapeutics, Inc. (Nasdaq: STOK) presentó un Formulario 8-K el 10 de julio de 2025 bajo el punto 7.01 (Regulación FD). El documento indica que la empresa emitió un comunicado de prensa (Anexo 99.1) anunciando la presentación de datos de un análisis que informó el diseño del estudio de Fase 3 EMPEROR planificado y evaluó los posibles efectos del régimen de dosificación propuesto para zorevunersen. No se incluyeron métricas financieras, resultados del estudio ni cronogramas en el 8-K. La información se proporciona (no se presenta) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o Securities Act a menos que se indique expresamente.
Stoke Therapeutics, Inc. (나스닥: STOK)은 2025년 7월 10일 항목 7.01(Regulation FD)에 따라 Form 8-K를 제출했습니다. 제출 문서에 따르면 회사는 계획된 3상 EMPEROR 연구 설계에 정보를 제공한 분석 데이터와 제안된 zorevunersen 투여 요법의 잠재적 영향을 평가한 내용을 발표하는 보도자료(증빙자료 99.1)를 발행했습니다. 8-K에는 재무 지표, 연구 결과 또는 일정이 포함되지 않았습니다. 이 정보는 제공된 것이며(제출된 것이 아님) 따라서 특별히 명시되지 않는 한 다른 Exchange Act 또는 Securities Act 제출 문서에 참조로 포함되지 않습니다.
Stoke Therapeutics, Inc. (Nasdaq : STOK) a déposé un formulaire 8-K le 10 juillet 2025 en vertu de l’article 7.01 (Règlement FD). Le dépôt indique que la société a publié un communiqué de presse (Annexe 99.1) annonçant la présentation des données d’une analyse ayant guidé la conception de l’étude de phase 3 EMPEROR prévue et évalué les effets potentiels du schéma posologique proposé pour le zorevunersen. Aucune donnée financière, résultat d’étude ou calendrier n’a été inclus dans le 8-K. Les informations sont fournies (non déposées) et ne sont donc pas incorporées par référence dans d’autres dépôts en vertu de l’Exchange Act ou du Securities Act, sauf indication contraire.
Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. In der Einreichung wird mitgeteilt, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) veröffentlicht hat, in der die Präsentation von Daten einer Analyse angekündigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas von Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpläne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher, sofern nicht ausdrücklich angegeben, nicht in andere Einreichungen nach dem Exchange Act oder Securities Act aufgenommen.
- None.
- None.
Insights
TL;DR: Routine Reg FD update; provides visibility on Phase 3 planning but lacks efficacy or financial data.
The 8-K simply notifies investors that Stoke has released supportive data used to shape its upcoming Phase 3 EMPEROR trial of zorevunersen. Because the document omits the data itself, it offers limited incremental insight into clinical risk or valuation. The disclosure is furnished under Item 7.01, signalling that management views it as informational rather than materially transformative. Absent study results or new guidance, I classify the immediate market impact as neutral.
Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la società ha diffuso un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione dei dati di un’analisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR pianificato e ha valutato i potenziali effetti del regime di dosaggio proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite (non depositate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell’Exchange Act o del Securities Act, salvo diversa indicazione.
Stoke Therapeutics, Inc. (Nasdaq: STOK) presentó un Formulario 8-K el 10 de julio de 2025 bajo el punto 7.01 (Regulación FD). El documento indica que la empresa emitió un comunicado de prensa (Anexo 99.1) anunciando la presentación de datos de un análisis que informó el diseño del estudio de Fase 3 EMPEROR planificado y evaluó los posibles efectos del régimen de dosificación propuesto para zorevunersen. No se incluyeron métricas financieras, resultados del estudio ni cronogramas en el 8-K. La información se proporciona (no se presenta) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o Securities Act a menos que se indique expresamente.
Stoke Therapeutics, Inc. (나스닥: STOK)은 2025년 7월 10일 항목 7.01(Regulation FD)에 따라 Form 8-K를 제출했습니다. 제출 문서에 따르면 회사는 계획된 3상 EMPEROR 연구 설계에 정보를 제공한 분석 데이터와 제안된 zorevunersen 투여 요법의 잠재적 영향을 평가한 내용을 발표하는 보도자료(증빙자료 99.1)를 발행했습니다. 8-K에는 재무 지표, 연구 결과 또는 일정이 포함되지 않았습니다. 이 정보는 제공된 것이며(제출된 것이 아님) 따라서 특별히 명시되지 않는 한 다른 Exchange Act 또는 Securities Act 제출 문서에 참조로 포함되지 않습니다.
Stoke Therapeutics, Inc. (Nasdaq : STOK) a déposé un formulaire 8-K le 10 juillet 2025 en vertu de l’article 7.01 (Règlement FD). Le dépôt indique que la société a publié un communiqué de presse (Annexe 99.1) annonçant la présentation des données d’une analyse ayant guidé la conception de l’étude de phase 3 EMPEROR prévue et évalué les effets potentiels du schéma posologique proposé pour le zorevunersen. Aucune donnée financière, résultat d’étude ou calendrier n’a été inclus dans le 8-K. Les informations sont fournies (non déposées) et ne sont donc pas incorporées par référence dans d’autres dépôts en vertu de l’Exchange Act ou du Securities Act, sauf indication contraire.
Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. In der Einreichung wird mitgeteilt, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) veröffentlicht hat, in der die Präsentation von Daten einer Analyse angekündigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas von Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpläne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher, sofern nicht ausdrücklich angegeben, nicht in andere Einreichungen nach dem Exchange Act oder Securities Act aufgenommen.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | ||
| of incorporation) |
(Address of principal executive offices) |
(ZIP Code) |
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
Election of New Director. Effective July 10, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Joseph L. (Jay) Hooley as an independent Class III Director and appointed him as a member of its Audit Committee and Governance and Corporate Responsibility Committee. To effect Mr. Hooley’s election as a Class III Director, the Board increased the number of Directors constituting the Board from nine to ten and the number of Class III Directors from three to four. It is expected that Mr. Hooley will stand for election by stockholders as a Class III Director at the Company’s 2028 annual meeting of stockholders.
There are no related person transactions (or proposed related person transactions) with respect to Mr. Hooley reportable under Item 5.02(d) of Form 8-K and Item 404(a) of Regulation S-K since the beginning of the Company’s last fiscal year.
Mr. Hooley will receive the same compensation as is paid to the Company’s other non-employee Directors, as described in the section entitled “Corporate Governance – Non-Employee Director Compensation” in the Company’s Proxy Statement filed with the Securities and Exchange Commission on March 28, 2025, which description is incorporated herein by reference. The cash fee to be paid to Mr. Hooley in the third quarter of 2025 will be prorated to reflect the effective date of his election to the Board. Annual deferred stock unit or restricted stock unit and stock option grants were made to non-employee Directors on May 7, 2025, the date of the Company’s 2025 annual meeting of stockholders. Since Mr. Hooley was not serving as a Director at that time, such grants will be made to him on September 1, 2025, and the award values will be prorated to reflect the portion of the year during which he will serve on the Board, specifically from July 10, 2025 until the Company’s 2026 annual meeting of stockholders. In addition, Mr. Hooley will be eligible to defer all or any portion of his cash fees and the entire amount of each restricted stock unit grant pursuant to the terms of the Company’s Director Deferred Compensation Plan.
On July 10, 2025, the Company issued a press release regarding Mr. Hooley’s election to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibit relating to Item 5.02 shall be deemed to be furnished, and not filed.
| 99.1 | Press Release entitled "IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors" dated July 10, 2025. |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IDEXX LABORATORIES, INC. | ||
| Date: July 10, 2025 | By: | /s/ Sharon E. Underberg |
| Sharon E. Underberg | ||
| Executive Vice President, General Counsel and Corporate Secretary | ||
2
FAQ
What did Stoke Therapeutics (STOK) announce in its July 10, 2025 Form 8-K?
Does the 8-K include actual results from the Phase 3 EMPEROR study?
Is the information in Exhibit 99.1 considered "filed" with the SEC?
Were any financial statements or earnings figures provided in this 8-K?
What is the trading symbol and exchange listing for Stoke Therapeutics?
